Specific serum and mucosal antitoxin levels were determined by enzyme-linked immunosorbent assays in rats immunized with Escherichia coli heat-labile enterotoxin (LT). Immunization by means of a parenteral prime followed by peroral boosts was the only approach that aroused titers of both serum immunoglobulin G (IgG) antitoxin and mucosal secretory IgA antitoxin that were increased fourfold or more over control values. Primary parenteral immunization was effective when given either intraperitoneally or subcutaneously with either Freund complete adjuvant or alum as the adjuvant. The magnitude of the mucosal secretory IgA antitoxin response and the degree of protection against challenge with either LT or viable LT-producing organisms were related to the number and dosage of peroral boosts. LT antigenicity, as determined by enzyme-linked immunosorbent assay, was progressively reduced by toxoiding it with increasing amounts of glutaraldehyde or a carbodiimide; when LT antigenicity was reduced by >50%, the effectiveness of the toxoid in stimulating mucosal antitoxin and providing protection was compromised. Strong protection extended for more than 6 weeks only in rats immunized with a sufficient peroral dosage of LT to arouse mucosal secretory IgA antitoxin titers at least fourfold greater than those of controls. These observations indicate that the ability of LT to stimulate a mucosal secretory IgA antitoxin response is dependent on the antigenicity, route, and dosage of this immunogen; they suggest that the duration of protection in animals immunized by the peroral route is related to the extent of arousal of mucosal secretory IgA antitoxin.
Specific serum and mucosal antitoxin levels were determined by enzyme-linked immunosorbent assays in rats immunized with Escherichia coli heat-labile enterotoxin (LT). Immunization by means of a parenteral prime followed by peroral boosts was the only approach that aroused titers of both serum immunoglobulin G (IgG) antitoxin and mucosal secretory IgA antitoxin that were increased fourfold or more over control values. Primary parenteral immunization was effective when given either intraperitoneally or subcutaneously with either Freund complete adjuvant or alum as the adjuvant. The magnitude of the mucosal secretory IgA antitoxin response and the degree of protection against challenge with either LT or viable LT-producing organisms were related to the number and dosage of peroral boosts. LT antigenicity, as determined by enzyme-linked immunosorbent assay, was progressively reduced by toxoiding it with increasing amounts of glutaraldehyde or a carbodiimide; when LT antigenicity was reduced by >50%, the effectiveness of the toxoid in stimulating mucosal antitoxin and providing protection was compromised. Strong protection extended for more than 6 weeks only in rats immunized with a sufficient peroral dosage of LT to arouse mucosal secretory IgA antitoxin titers at least fourfold greater than those of controls. These observations indicate that the ability of LT to stimulate a mucosal secretory IgA antitoxin response is dependent on the antigenicity, route, and dosage of this immunogen; they suggest that the duration of protection in animals immunized by the peroral route is related to the extent of arousal of mucosal secretory IgA antitoxin.
Protection against the secretory effect of intestinal contamination by some species of enterotoxigenic enteric pathogens has been achieved in experimental animals by immunization with the appropriate toxin or toxoid (10, 14, 20) . The nature of the protective antitoxin (AT) response depends on the route of delivery: in the case of cholera toxin (CT), immunization given by the parenteral route arouses primarily a serum immunoglobulin G (IgG) AT response, whereas immunization by the intestinal route evokes principally an IgA AT response within the intestinal mucosa. The respective AT titers correlate with the degree of protection in both instances (11, 14, 16, 23) . Cholera toxoid differs from CT in that primary parenteral immunization is necessary for effective subsequent intestinal immunization (15, 17, 19, 20) .
Immunization of rats with the Escherichia coli heat-labile enterotoxin (LT) provides protection against challenge with homologous or heterologous serotypes of E. coli which elaborate LT, either alone (LT'/ST-) or together with the heat-stable toxin (ST) (LT+/ST+) (4, 8, 10) . This immunogen resembles cholera toxoid in that, in this animal model at least, it also requires primary parenteral immunization for peroral (p.o.) immunization to be effective (4-7). Immunization with LT given just by the parenteral route, or by a parenteral prime followed by p.o. boosts, has been found to yield dose-dependent increases in serum IgG AT levels which correlate with the degree of protection (6, 7) , but the mucosal AT response to immunization with this toxin has not been ascertained so far.
In the present study, we used the enzymelinked immunosorbent assay (ELISA) to quantitate both the serum and the mucosal AT responses to immunization with LT. Factors affecting the mucosal secretory IgA (sIgA) AT response, including the antigenicity, route of administration, and dosage of the LT immunogen, were identified, and the relationship between levels of this AT and the degree of imme-IMMUNIZATION WITH E. COLI ENTEROTOXIN 1087 diate and extended protection was evaluated.
MATERIALS AND METHODS
Immunogens. The LT holotoxin was prepared in purified form by the methods of Clements and Finkelstein (2) from E. coli 711 (FlLT), a transformed K-12 derivative bearing the LT gene(s) of the Ent plasmid from porcine strain P307. Its homogeneity was confirmed by polyacrylamide gel electrophoresis. Concentrations of LT and its toxoids are expressed on the basis of protein concentration as determined by the method of Lowry et al. (12) .
LT toxoids were obtained by exposing LT either to 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC) for 18 h at 4°C at EDAC-toxin ratios of from 10 to 75 by weight (4.8 x 103 to 35.8 x 103 M) or to glutaraldehyde for 96 h at 37°C at molar ratios of from 100 to 600, which are the same as those that have been used to toxoid CT (21) . The toxoids were subsequently exhaustively dialyzed against water to remove the toxoiding agents. The toxicity of the toxoids was compared with that of unattenuated LT by testing twofold serial dilutions of trypsinized LT and toxoids in the Y1 adrenal cell assay (22) . Values for the toxoids are expressed as percentages of the minimum dosage of that material compared with that of LT which yielded a positive response. The antigenicity of the toxoids was assessed in an ELISA by comparing the response of twofold serial dilutions of LT or the toxoids laid down as the solid phase against goat monospecific hyperimmune antiserum to LT. Concentrations yielding an optical density of 0.600 at 410 nm were compared, and the results for the toxoids were expressed as percentages of the values for unattenuated LT (Fig. 1) .
Immunization procedures. Eight-week-old SpragueDawley rats were used. Unless otherwise specified, all parenteral immunizations were administered by the intraperitoneal (i.p.) route with Freund complete adjuvant for primary immunization and Freund incomplete adjuvant for boosting. LT (4, 9) . Each datum point was determined for three to five rats, and the values reported are for the mean + standard error of the mean of the degree of reduced secretion in immunized rats as compared with unimmunized rats similarly challenged. Under these challenge conditions, a 50% reduction in secretion is referred to as significant protection since it represented a statistically significant difference (P < 0.001 as determined by Student's t test for two independent means) between the values in immunized and control animals.
AT titers. Serum and mucosal AT titers to the LT holotoxin were determined by ELISA (24) with immobilized LT. In these experiments, rabbit anti-rat IgG together with goat anti-rabbit antiserum conjugated to alkaline phosphatase and goat anti-rat sIgA together with rabbit anti-goat antiserum conjugated to alkaline phosphatase (Miles Laboratories, Inc., Elkhart, Ind.) were used. The AT titer was the maximum dilution which gave an optical density of 0.100 or more measured spectrophotometrically at 410 nm. Values reported are for the increase in the reciprocal of the geometric mean titer for samples from five or more rats in each test group over the value of 1:2 obtained in a control group of 10 unimmunized rats; thus, a fivefold increase in immunized animals represented a titer of 1:64.
Mucosal AT titers were measured in intestinal washings. Ligated loops were emptied, rinsed with 5 ml of normal saline, and centrifuged; the supernatant was sterile filtered and then lyophilized and stored at -60°C until it was reconstituted at a constant volume for assay. To exclude the possibility that AT levels might be spuriously reduced by binding of the AT to the antigen that was placed in the challenge loops, AT titers were compared in washings from both challenge and adjacent loops in each rat; the values were the same.
None of the immunized rats had increased titers of serum sIgA or mucosal IgG AT; therefore, these determinations are not reported. AT values referred to as serum AT indicate IgG AT, and those referred to as mucosal AT indicate sIgA AT.
1.0 0\\. LT (Fig. 2) . A total p.o. dosage of 200 ,ug failed to raise AT titers or to provide protection when given in two boosts, but this dosage did yield a fourfold increase in serum AT titers and a significant degree of protection when it was divided into four boosts. Immunizations with both two and four boosts aroused at least fourfold increases in serum and mucosal AT titers associated with significant protection when given at a total dosage of 500 ,ug. Doubling the total p.o. dosage to 1,000 gxg increased AT titers in both groups further, to at least five or six times their original levels, and produced an increased degree of protection in those immunized with two boosts.
(iv) Antigenicity of the LT immunogen. Exposure of LT to increasingly larger amounts of either glutaraldehyde or EDAC resulted in a progressive decline in antigenicity (Fig. 3) well as in toxicity; at the maximum amount of toxoiding agent used, the glutaraldehyde toxoid had 32% residual LT toxicity, and the EDAC toxoid had <1% residual toxicity. To determine whether reduced antigenicity, as determined by ELISA, correlated with compromised effectiveness as an immunogen, an LT toxoid which had 43% retained antigenicity after exposure to EDAC at a ratio of 45:1 was used to immunize rats. The effectiveness of this toxoid was compared with that of LT when both were given as a 100-,ug i.p. prime followed by two p.o. boosts of various dosages (Fig. 4) . Four times more toxoid than unattenuated LT was needed to achieve fourfold elevations of serum and mucosal AT titers and to afford a significant degree of protection.
Relationship of mucosal AT to extended protection. Serum and mucosal AT titers and the degree of protection were monitored over a 3-month period in two groups of rats (Fig. 5) . Both groups were immunized by an i.p. prime followed by four p.o. boosts of two different dosages. Both groups had at least fourfold elevations of serum AT titers and were significantly protected immediately after immunization, but only those which had received a total p.o. dosage of 1,000 ,ug had a fourfold increase or more in mucosal AT titers.
Serum AT titers remained unchanged at 6 weeks after immunization in both groups, but significant protection persisted only in those with elevated mucosal AT titers. By the end of 12 weeks, serum and mucosal AT titers had fallen to less than fourfold increases, and the degree of protection was reduced in both groups. Based on the rate of fall in the degree of protection, a significant degree of protection persisted for approximately twice as long in those rats which had elevated mucosal AT titers. DISCUSSION Several techniques have been developed to document a specific mucosal IgA AT response to intestinal immunization with CT: the enumeration of specific antitoxin-containing cells within the lamina propria by immunofluorescence (11, (13) (14) (15) , quantitation by ELISA of AT present in intestinal washings (15, 25) , and determination by ELISA of the amount of AT produced during in vitro tissue culture of intestinal tissue (23) . These approaches have shown that the magnitude of the mucosal IgA AT response to immunization with CT or toxoid is related to the number and dosage of intestinal immunizations and that mucosal AT levels correlate with the degree of protection against challenge with either toxin or viable Vibrio cholerae.
The results of the present study established the fact that intestinal immunization with LT also arouses a dose-dependent response of mucosal sIgA AT. It is well recognized that parenteral immunization can serve as an effective prime for a mucosal IgA response to a locally applied antigen (3, 15) , and certain immunogens appear to require this when given by the intestinal route to achieve an immunological response. Cholera toxoid is effective as an intestinal immunogen only when given after parenteral primary immunization; this can be achieved by s.c. priming in dogs, but only priming by the i.p. route is effective in rats (15, 17, 20 have previously shown that, on a molar basis, the LT holotoxin is a more effective immunogen than other forms of LT, such as that obtained by polymyxin release (6) . Past experience with other toxins, such as CT (13, 21) , has shown that toxoiding usually reduces the antigenicity of the toxin, the degree of which depends on the specific toxoiding agent and the amount and conditions used for toxoiding. We found that exposure of LT to increasing amounts of either of two toxoiding agents, glutaraldehyde and the carbodiimide EDAC, resulted in a progressive reduction in LT antigenicity as determined by an ELISA and that reduced antigenicity of the toxoid, as demonstrated by this assay, correlated with compromised effectiveness of the toxoided LT to evoke an AT response and provide protection in immunized animals. Our findings indicate that preliminary screening of toxoids for residual antigenicity by means of an ELISA can be used to expedite the evaluation of toxoiding agents and conditions by obviating the need to examine all toxoid preparations with the more cumbersome and time-consuming animal studies.
Although the respective contributions of serum and mucosal antibodies to protection against enterotoxigenic enteric pathogens remain to be clarified, the limited evidence available suggests that mucosal sIgA AT is primarily responsible for extended protection. Parenteral immunization yields only transient protection, whereas parenteral-p.o. immunization provides extended protection both in dogs immunized with cholera toxoid (15, 19, 20) and in rats immunized with LT (5, 7). In the present study, we found that strong protection extended for a longer period of time in rats which had received a sufficient p.o. dosage to achieve elevated mucosal sIgA AT (15) .
